Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients.

Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways.

The company's pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors.

It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program.

The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.